Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTKN7QR)

• DTT Name: BDNF/NT-3 growth factors receptor (TrkB) DTT Info
• Gene Name: NTRK2

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Entrectinib	DMMPTLH	Non-small-cell lung cancer	2C25	Approved	[1]
Larotrectinib	DM26CQR	Solid tumour/cancer	2A00-2F9Z	Approved	[2]

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[3]

11 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3-amino-5-benzyl-substituted indazole derivative 1	DMFDURZ	Chronic pain	MG30	Patented	[4]
Azaindazole amide derivative 1	DMJWH4B	Chronic pain	MG30	Patented	[4]
Cyclopenta[d]pyrimidine derivative 1	DMKM6BY	N. A.	N. A.	Patented	[5]
Macrocycle derivative 13	DM1KBSV	Cell proliferative disorder	FB86	Patented	[5]
PMID28270010-Compound-Figure24-b	DM0QHLK	N. A.	N. A.	Patented	[5]
PMID28270010-Compound-Figure5-1	DM2YAPJ	N. A.	N. A.	Patented	[5]
PMID28270010-Compound-Figure5-2	DMK3GRZ	N. A.	N. A.	Patented	[5]
PMID28270010-Compound-Figure5-3	DMSOT1R	N. A.	N. A.	Patented	[5]
PMID28270021-Compound-WO2015042088Example4	DM6KXOQ	Chronic pain	MG30	Patented	[4]
PMID28270021-Compound-WO2016054807Example1	DMD5QEL	Chronic pain	MG30	Patented	[4]
Pyrrolo[2,3-d]pyrimidine derivative 4	DME0WSR	Chronic pain	MG30	Patented	[4]

4 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD1332	DM0PVD9	Discovery agent	N.A.	Investigative	[6]
GNF-5837	DMYJO13	Discovery agent	N.A.	Investigative	[7]
PMID24432909C8e	DMEGAZS	Discovery agent	N.A.	Investigative	[8]
TrkB NAM	DMBZI5F	Neurodegenerative disorder	8A20-8A23	Investigative	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [3] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [4] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
• [5] Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818).
• [7] Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5.
• [8] Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87.